Majority Of US Patent Thickets Filed Post-FDA Approval, Study Finds

The Investigation Looked At Top 10 Selling Prescription Drugs In 2021

As different US authorities keep pointing fingers at each other over who is responsible for improper patent listings, a study looks at patent applications that are filed after an FDA approval.

Businessman in a maze
• Source: Shutterstock

A new investigation has found that 72% of patent applications linked to the 10 top-selling prescription drugs in the US for 2021 were filed after receiving approval from the US Food and Drug Administration.

More from Legal & IP

Teva Provigil ‘Pay For Delay’ Fines Should Stand, AG Says

 
• By 

Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.

Five-Year Extension Found Just, As Aurobindo Loses On US Sugammadex Appeal

 
• By 

In a precedential decision, the US Court of Appeals for the Federal Circuit has determined the meaning of the language “the patent” as it applies to patent-term extensions for reissued patents, in the context of Aurobindo’s bid to wipe out a reissued patent shielding Merck & Co’s Bridion (sugammadex) injectable.

MSN’s US Entresto Generic Blocked In Part For Being Too Similar To The Brand

 
• By 

Novartis’ multi-front legal battle against MSN Laboratories over its Entresto blockbuster in the US has taken yet another twist, with a federal district court in New Jersey finding that a preliminary injunction was warranted against MSN’s product on the basis of infringement of Novartis’ trade dress.

Walmart Pursues Generics Industry Leaders Over Price-Fixing

 
• By 

Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.

More from Generics Bulletin

Teva Provigil ‘Pay For Delay’ Fines Should Stand, AG Says

 
• By 

Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs

 
• By 

Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.

What’s Next? Five Things To Look Out For In April

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.